Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2026 | $0.12 | 2026-06-26 | 2026-06-26 |
| May 27, 2026 | $0.17 | 2026-05-22 | 2026-05-22 |
| April 28, 2026 | $0.15 | 2026-04-24 | 2026-04-24 |
| March 31, 2026 | $0.25 | 2026-03-27 | 2026-03-27 |
| March 3, 2026 | $0.31 | 2026-02-27 | 2026-02-27 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 14 dividend payments over the past 1 years.
- Total Returned Value: Investors who held IMRA shares during this period received a total of $28.51 per share in dividend income.
- Latest Payout: The most recent dividend of $0.12/share was paid 18 days ago, on June 30, 2026.
- Yield & Schedule: IMRA currently pays dividends monthly with an annual yield of 120.33%.
- Dividend Growth: Since 2025, the dividend payout has decreased by 98.7%, from $9.33 to $0.12.
Company News
OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics (ELVN) for approximately $39 million on June 22, 2026, representing 11.60% of its holdings. Despite the partial exit following a 130% stock rally, OrbiMed retains over 6.5 million shares, signaling continued confidence. Enliven, a clinical-stage biotech focused on cancer therapies, has ...
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a ...
Enliven Therapeutics' Chief Medical Officer Helen Collins sold 5,000 shares worth approximately $199,000 on May 18, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Collins retains over 150,000 shares in the company, suggesting confidence in the biotech firm. The sale occurred during a period of strong stock performa...
Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara’s sto...
